SCHEMBL12707403

SCHEMBL12707403

Cc1ccc(Br)cc1-c1cnccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.40
TDO2 P48775 1/20 0.38
CYP11B1 P15538 4/20 0.37
CYP11B2 P19099 4/20 0.37
RPS6KA3 P51812 4/20 0.37
KMT2A Q03164 1/20 0.37
KIT P10721 1/20 0.37
PDE10A Q9Y233 2/20 0.36
GABRA1 P14867 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
IDO1 P14902 1/20 0.35
CHUK O15111 1/20 0.35
AGPAT2 O15120 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12707406 0.86 TDO2 (0.42) PTGS2TDO2CYP11B1CYP11B2KMT2A
SCHEMBL12707404 0.80 PLA2G7 (0.44) PTGS2TDO2CYP11B1CYP11B2RPS6KA3
SCHEMBL12707335 0.79 TDO2 (0.38) PTGS2TDO2CYP11B1CYP11B2KMT2A
SCHEMBL20124291 0.77 IDO1 (0.41) RPS6KA3KMT2AKITIDO1CHUK
SCHEMBL890757 0.75 S100A4 (0.46) IDO1AGPAT2
SCHEMBL22907284 0.74 TDO2 (0.41) PTGS2TDO2CYP11B1CYP11B2KMT2A
SCHEMBL2648933 0.74 NUDT1 (0.42) RPS6KA3GABRA1GABRA5GABRA3GSK3B
SCHEMBL6222583 0.71 CYP11B1 (0.54) CYP11B1CYP11B2KMT2A
SCHEMBL527540 0.70 ALDH1A1 (0.39) PTGS2TDO2CYP11B1CYP11B2RPS6KA3
SCHEMBL26462975 0.70 SRC (0.47) PTGS2TDO2CYP11B1CYP11B2RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082147-A1 SUBSTITUTED IMIDAZOTRIAZINES CONCERT PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082147-A1 SUBSTITUTED IMIDAZOTRIAZINES GABRA5, GABRA3, GABRA2 PTGS2 1242/4885TDO2 1858/4885CYP11B1 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.